News Related to Perjeta

Related coverage linked through entity extraction aliases.

CD47 Expression Levels Predict Response to Evorpacept Plus Zanidatamab in HER2+ Breast Cancer

Mar 11, 2026

Exploratory analysis from a phase 1/2 trial shows CD47 expression levels predict response to evorpacept plus zanidatamab in heavily pretreated HER2-positive metastatic breast cancer patients, supporting biomarker-driven patient selection.

Daiichi Sankyo Names John Tsai as New Global Head of R&D

Feb 20, 2026

Former Novartis executive John Tsai has been appointed global head of R&D at Daiichi Sankyo, replacing Ken Takeshita effective April 1. Tsai brings over 25 years of leadership experience in drug development.